Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.51 USD
+0.02 (0.63%)
Updated Apr 26, 2024 03:36 PM ET
After-Market: $2.49 -0.02 (-0.62%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLLS 2.51 +0.02(0.63%)
Will CLLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLLS
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
Other News for CLLS
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
Cellectis Presents Novel TALENĀ® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis Unveils Groundbreaking Gene-Editing Advances
Cellectis Unveils Gene Therapy Breakthrough
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs